
BioCryst Pharmaceuticals (BCRX) Stock Forecast & Price Target
BioCryst Pharmaceuticals (BCRX) Analyst Ratings
Bulls say
BioCryst Pharmaceuticals Inc. has demonstrated significant growth, with Orladeyo sales reaching $124 million in 4Q24, reflecting a 37% year-over-year increase, and the company has raised its 2025 revenue guidance to a range of $535 million to $550 million, indicating strong momentum. Physician sentiment toward Orladeyo has notably improved, with 59% of physicians now extremely likely to prescribe the treatment, suggesting a favorable outlook for market penetration and sales growth. The favorable reimbursement dynamics, coupled with sustained efficacy and tolerability of Orladeyo, support the expectation of reaching $1 billion in peak worldwide sales, further enhancing the company’s growth potential in the biotechnology sector.
Bears say
BioCryst Pharmaceuticals Inc. faces a negative outlook primarily due to ongoing financial losses, having reported a net loss of $26.8 million in the fourth quarter of 2024 and $88.9 million for the fiscal year 2024, indicating that profitability remains out of reach for the foreseeable future. Additionally, the company's anticipated flat to lower sales of Orladeyo in 1Q24 and projected revenue decline in 1Q25 due to patient reauthorization issues highlight significant challenges in maintaining revenue streams. Furthermore, potential risks such as failures in clinical trials, regulatory setbacks, and a limited commercial opportunity contribute to a cautious investment thesis regarding the company's long-term financial viability.
This aggregate rating is based on analysts' research of BioCryst Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
BioCryst Pharmaceuticals (BCRX) Analyst Forecast & Price Prediction
Start investing in BioCryst Pharmaceuticals (BCRX)
Order type
Buy in
Order amount
Est. shares
0 shares